During EC therapy, ≥grade 3 hematological toxicities included neutropenia (61%), leukopenia (37%), FN (6.1%), anemia (2%), and an ASL/ALT increase (2%), while ≥grade 3 nonhematological toxicities included nausea (2%), appetite loss (2%), phlebitis (2%), and alopecia (2%). The gene discussed is GPT; the disease is Decreased total leukocyte count.